Overview of the drug development pipeline for Cholangiocarcinoma
Cholangiocarcinoma, is termed as bile duct cancer, due to its originality in the bile ducts. This cancer is the most common type of biliary tract malignancy and may also originate in the liver and extrahepatic bile ducts. This cancer is identified to be incurable and fatal, and relatively rare. Cholangiocarcinoma is diagnosed through blood tests, biliary tree imaging, surgery, pathology, and abdominal imaging. This disease is more prevalent in individuals aged above 65 years of age. Technavio’s market research analysts have identified the uncontrolled division of cells in the biliary tract region that causes the tumor to form and grow, as one of the primary reasons behind the significant investments in the drug development for therapeutics for Cholangiocarcinoma in the pharmaceutical industry.
According to this pipeline analysis report, this pipeline consists of major drug development molecules in the Phase II drug development stage, followed by the Phase I drug development stage. Our market research analysts have also identified the amount of drug molecules are under the phase I/II and pre-clinical drug development stage. The pipeline landscape in the pipeline analysis report also mentions the small percentage of drug development molecules that are in the phase III stage.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of Cholangiocarcinoma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- SUPREMECURE PHARMA
- VASGENE THERAPEUTICS
- DORMANT MOLECULES
Therapeutic assessment of the drug development pipeline for Cholangiocarcinoma by route of administration
- Oral
- Intravenous
- Subcutaneous
The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the majority of total therapeutics for Cholangiocarcinoma are being developed for oral administration.
Therapeutic assessment of the drug development pipeline for Cholangiocarcinoma by therapeutic modality
- Small molecules
- Monoclonal antibody
- Stem cell
- Plant-derived molecule
- Fusion protein
- Vaccine
According to this pipeline analysis report, majority of the molecules in the drug development pipeline for chondrosarcoma are being developed in the form of small molecules. These molecules are chemically manufactured active substances that bind with specific biological macromolecules and act as an effector and alter the activity of the target cell.
Technavio also offers customization on reports based on specific client requirement.